title: A retrospective study of endophtalmitis rates comparing quinolone antibiotics.
abstract: OBJECTIVE
  To compare endophthalmitis rates between topical quinolone antibiotics over a four-year period in a university setting.
  
  
  METHODS
  Retrospective, cross-sectional (prevalence) study.
  
  
  METHODS
  
  
  
  METHODS
  Nine thousand seventy-nine patients who underwent a phacoemulsification procedure at a University Eye Center.
  
  
  METHODS
  The following interventions were conducted: use of a nosocomial infectious reporting database retrospective analysis of prospectively collected data to establish endophthalmitis rates; prevalence analysis of postoperative quinolone antibiotics; analysis of endophthalmitis rate vs postoperative quinolone prescribed.
  
  
  METHODS
  Occurrence of endophthalmitis after cataract surgery.
  
  
  RESULTS
  During a four-year period involving 9079 phacoemulsification procedures, 26 cases of bacterial postoperative endophthalmitis were reported (rate = 0.286%). Eight of the 26 cases were considered complicated; 18 cases were uncomplicated. Among cases performed during this period, postoperative prescription volumes for ciprofloxacin (Ciloxan, Alcon Laboratories, Inc., Fortworth, Texas) and ofloxacin (Ocuflox, Allergan, Inc., Irvine, California) antibiotic drops were nearly identical, with 4538 patients receiving ciprofloxacin (49.98%) and 4541 patients receiving ofloxacin (50.02%). There were 22 endophthalmitis patients (85%) who had used topical ciprofloxacin and 4 patients (15%) who had used topical ofloxacin postoperatively. The difference in infectious rates between antibiotics was highly significant (P < .00026). For uncomplicated cases, 14 patients received ciprofloxacin and 4 patients received ofloxacin. This difference was also significant (P < .015).
  
  
  CONCLUSIONS
  Differences in pharmacokinetic and pharmacodynamic properties exist among quinolone antibiotics, which may affect endophthalmitis incidence following cataract surgery.
authors.affiliation: Department of Pharmacy Services, University of Utah, John A. Moran Eye Center, Salt Lake City, Utah 84132, USA. mike.jensen@hsc.utah.edu
authors.forename: Michael K
authors.initials: MK
authors.lastname: Jensen
authors.forename: Richard G
authors.initials: RG
authors.lastname: Fiscella
authors.forename: Alan S
authors.initials: AS
authors.lastname: Crandall
authors.forename: Majid
authors.initials: M
authors.lastname: Moshirfar
authors.forename: Barbara
authors.initials: B
authors.lastname: Mooney
authors.forename: Trevin
authors.initials: T
authors.lastname: Wallin
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Olson
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D017723:Drug Utilization Review; D009877:Endophthalmitis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D018918:Phacoemulsification; D011183:Postoperative Complications; D015995:Prevalence; D012189:Retrospective Studies; D014589:Utah / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D015242:Ofloxacin